Clinical Trial Update: A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients [Phase 3]

View source ↗

Summary

A Phase III trial is evaluating taletrectinib versus standard therapy in ROS1-positive locally advanced or metastatic non-small cell lung cancer; the study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Taletrectinib (taletrectinib)

Snippet

Sponsor: Nuvation Bio Inc. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: RECRUITING